PRA Health Sciences, Inc. (NASDAQ:PRAH) had its price target boosted by Robert W. Baird from $82.00 to $83.00 in a report issued on Tuesday. Robert W. Baird currently has an outperform rating on the medical research company’s stock.
PRAH has been the subject of several other research reports. Bank of America Corporation initiated coverage on shares of PRA Health Sciences in a research note on Monday, June 26th. They issued a buy rating and a $89.00 price target for the company. Credit Suisse Group reissued an outperform rating and issued a $76.00 price target (up previously from $69.00) on shares of PRA Health Sciences in a research note on Tuesday, June 6th. Jefferies Group LLC set a $73.00 price target on shares of PRA Health Sciences and gave the company a buy rating in a research note on Thursday, June 1st. BidaskClub cut shares of PRA Health Sciences from a strong-buy rating to a buy rating in a research note on Monday, July 31st. Finally, Citigroup Inc. reissued a buy rating and issued a $90.00 price target (up previously from $73.00) on shares of PRA Health Sciences in a research note on Wednesday, June 28th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. PRA Health Sciences has an average rating of Buy and an average price target of $78.00.
PRA Health Sciences (NASDAQ PRAH) opened at 74.20 on Tuesday. The stock has a market cap of $4.65 billion, a price-to-earnings ratio of 47.90 and a beta of 0.45. The company has a 50-day moving average price of $75.18 and a 200 day moving average price of $67.24. PRA Health Sciences has a 52-week low of $48.42 and a 52-week high of $80.99.
PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings results on Monday, August 7th. The medical research company reported $0.62 earnings per share for the quarter, missing the consensus estimate of $0.72 by $0.10. PRA Health Sciences had a net margin of 5.15% and a return on equity of 21.17%. The firm had revenue of $457.90 million during the quarter, compared to analysts’ expectations of $447.79 million. During the same period last year, the company earned $0.63 EPS. The business’s quarterly revenue was up .5% on a year-over-year basis. On average, analysts expect that PRA Health Sciences will post $3.18 earnings per share for the current year.
Institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its position in PRA Health Sciences by 43,947.8% in the first quarter. BlackRock Inc. now owns 2,857,381 shares of the medical research company’s stock worth $186,387,000 after buying an additional 2,850,894 shares during the last quarter. MARSHALL WACE ASIA Ltd bought a new position in PRA Health Sciences during the first quarter worth $82,935,000. Marshall Wace North America L.P. bought a new position in PRA Health Sciences during the first quarter worth $82,935,000. Harbour Capital Advisors LLC bought a new position in PRA Health Sciences during the second quarter worth $6,400,000. Finally, Wells Fargo & Company MN boosted its position in PRA Health Sciences by 321.6% in the first quarter. Wells Fargo & Company MN now owns 609,515 shares of the medical research company’s stock worth $39,760,000 after buying an additional 464,931 shares during the last quarter.
About PRA Health Sciences
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
What are top analysts saying about PRA Health Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PRA Health Sciences Inc. and related companies.